fda drug shortages semaglutide injection status resolved 2025 GLP-1 Drugs: Removes from the Shortage List Hims & Hers stock falls

NextechLabs' products are intended solely for laboratory research purposes and are not to be used for any other purposes, including but not limited to vitro diagnostic purpose, in food drugs, medical devices, or cosmetics for humans or animals or for commercial purposes

Common Saxenda side effects include nausea, vomiting, diarrhea, constipation, headaches, heartburn, runny nose, sneezing, cough and fatigue

Patients should seek immediate medical attention for and discontinue semaglutide if they experience: Severe, persistent abdominal pain (possible pancreatitis) Signs of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness) Symptoms of gallbladder disease (right upper quadrant pain, especially after meals) Severe hypoglycemia (when combined with insulin or sulfonylureas) Signs of kidney problems (decreased urination, swelling, fatigue) Suicidal thoughts or behaviors (particularly with Wegovy) Vision changes (especially in patients with diabetes and pre-existing retinopathy) Regular follow-up with healthcare providers is essential to monitor treatment response, adjust dosing, manage side effects, and assess cardiovascular risk factors including blood pressure, glucose control, and lipid profiles

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

This is why discussions about semaglutide and lipedema have become increasingly common within the lipedema community

Why retatrutide is not a candidate for screening Four reasons: First, retatrutide is not a controlled substance